{"ticker": {"uuid": "71565651-3550-4e9b-99dd-df15be539148", "symbol": "CTMX", "name": "CytomX Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Is CytomX (CTMX) One of the Best Growth Stocks Under $30 to Buy Now?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "Insider Monkey", "published_at": "2026-06-19T07:03:49+00:00", "published_display": "19 Jun 2026 07:03", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytomX Therapeutics (CTMX) CFO sells shares to cover RSU tax withholding", "summary": "CytomX Therapeutics CFO Christopher Ogden sold 1,624 shares of common stock on June 15, 2026, at an average price of $3.05 per share. This sale was a non-discretionary tax-related event to cover withholding obligations from the vesting of restricted stock units. Following the tra", "url": "https://www.stocktitan.net/sec-filings/CTMX/form-4-cytom-x-therapeutics-inc-insider-trading-activity-bf83af5e2c48.html", "source_name": "Stock Titan", "published_at": "2026-06-18T00:40:33", "published_display": "18 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytomX CFO Ogden sells $4,953 in company stock By Investing.com", "summary": "CytomX Therapeutics CFO Christopher Ogden sold 1,624 shares of company stock for $4,953 to cover tax obligations related to restricted stock units. Following the sale, Ogden directly holds 295,324 shares. This transaction occurs as CTMX shares are down 31% year-to-date and are co", "url": "https://in.investing.com/news/insider-trading-news/cytomx-cfo-ogden-sells-4953-in-company-stock-93CH-5460658", "source_name": "Investing.com India", "published_at": "2026-06-18T00:09:14", "published_display": "18 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytomX Therapeutics Inc (CTMX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides a revenue breakdown for CytomX Therapeutics Inc (CTMX). It notes that relevant data for business segments and current fiscal year quarters (FY2025, FY2025Q4, FY2025Q3, FY2025Q1) have not yet been disclosed by the company. However, it does sho", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ctmx/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T19:40:33", "published_display": "17 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10 Best Growth Stocks Under $30 to Buy Now", "summary": "The article highlights CytomX Therapeutics Inc. (NASDAQ: CTMX) as one of the best growth stocks under $30. It details CytomX's expanded research collaboration with Regeneron to develop next-generation bispecific cancer therapies, a deal potentially worth up to $4 billion. CytomX ", "url": "https://www.insidermonkey.com/blog/10-best-growth-stocks-under-30-to-buy-now-1782530/2", "source_name": "Insider Monkey", "published_at": "2026-06-17T17:09:14", "published_display": "17 Jun 2026 17:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytomX Therapeutics Inc (CTMX) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of CytomX Therapeutics Inc (CTMX), noting its current valuation score of 7.83 within the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -5.63 and mentions that P/B, P/S, and P/CF data have not been di", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ctmx/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T09:39:29", "published_display": "17 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytomX Therapeutics Inc (CTMX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "CytomX Therapeutics Inc (CTMX) has an earnings forecast score of 9.00, placing it 14th in the Biotechnology & Medical Research industry. Analysts have a \"Strong Buy\" rating with an average price target of $6.50. The company's expected revenue for the next quarter is $12.31M, with", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ctmx/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T08:39:29", "published_display": "17 Jun 2026 08:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Narrative Around CytomX Therapeutics (CTMX) Is Evolving With Recent Developments", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPSFU0a3JINkJxb2lNd21YZlpWdUc1aWU1Wkl0dXdZbElXeHhndkhhQ0d6eGt2am1DMXRVV2FBOVBmbDFOYkkwSzVtQm5GcXRXZHZSRGl4RE96ZVpFUWFwMlRYZGZLbVVOMXVJYVFIMmtSdWt6QTZTTzJkMktaZTEzZ3JtVi1aTU1TNzZ1cHRvemx4OU5RN2pOTUd0emUzX0s0bjRmZmotM2RyQQ?oc=5", "source_name": "Market source", "published_at": "2026-06-11T17:12:46+00:00", "published_display": "11 Jun 2026 17:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CTMX Stock Garners Price Target Revisions After Colorectal Cancer Trial Data: Jefferies Sees As Much As 230% Upside", "summary": "Following positive early-stage trial data for its lead asset Varseta-M in metastatic colorectal cancer, CytomX Therapeutics (CTMX) has received multiple price target revisions from analysts. Jefferies raised its price target to $16-$18, indicating a potential upside of up to 230%", "url": "https://stocktwits.com/news-articles/markets/equity/ctmx-stock-garners-price-target-revisions-after-colorectal-cancer-trial-data/cZ37k5oRIWc", "source_name": "Stocktwits", "published_at": "2026-06-09T22:39:32", "published_display": "09 Jun 2026 22:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Schulhoff & Co. Inc. Acquires Shares of 374,850 CytomX Therapeutics, Inc. $CTMX", "summary": "Schulhoff & Co. Inc. has acquired a new stake of 374,850 shares in CytomX Therapeutics, Inc. (NASDAQ:CTMX) during the fourth quarter, valued at approximately $1.6 million. This investment highlights broader institutional interest, with hedge funds and other institutional investor", "url": "https://www.marketbeat.com/instant-alerts/filing-schulhoff-co-inc-acquires-shares-of-374850-cytomx-therapeutics-inc-ctmx-2026-06-08/", "source_name": "MarketBeat", "published_at": "2026-06-08T14:09:17", "published_display": "08 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CTMX: Varseta-M shows strong efficacy in late-line CRC, with pivotal trials and new partnerships advancing", "summary": "CytomX Therapeutics (CTMX) has made significant progress with its Probody platform and expanded its collaboration with Regeneron, securing substantial funding. Their drug Varseta-M has shown strong efficacy and a manageable safety profile in advanced colorectal cancer, with pivot", "url": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3480519:0-ctmx-varseta-m-shows-strong-efficacy-in-late-line-crc-with-pivotal-trials-and-new-partnerships-advancing/", "source_name": "TradingView", "published_at": "2026-06-04T20:10:42", "published_display": "04 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytomX Therapeutics (Nasdaq:CTMX) - Stock Analysis", "summary": "CytomX Therapeutics (CTMX) is an oncology-focused biopharmaceutical company with a market cap of US$692.3m. The stock is considered 70.0% undervalued by analysts and its revenue is forecast to grow 37.37% per year, despite being currently unprofitable. Recent updates include posi", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ctmx/cytomx-therapeutics", "source_name": "Simply Wall Street", "published_at": "2026-06-04T12:08:44", "published_display": "04 Jun 2026 12:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytomX gains as licensing deal with Regeneron expands", "summary": "CytomX Therapeutics saw its shares rise following an expanded licensing agreement with Regeneron Pharmaceuticals. The deal builds on a collaboration initiated in 2021, focusing on the development of bispecific anticancer therapeutics using CytomX's Probody platform. Under the new", "url": "https://www.msn.com/en-us/health/other/cytomx-gains-as-licensing-deal-with-regeneron-expands/ar-AA24KeJw?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-06-03T16:41:29", "published_display": "03 Jun 2026 16:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inside CytomX\u2019s new cancer alliance with Regeneron, worth up to $4B", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNM1JqTGl0dWdIanhJU05QVl9DZ05sb3lSWS1uaDlwU0hJV29Pa1dncEE3VUJSeFg3YUxyQjVKNE9sdVhJdWhYVDI4UFNxTlhfdVoxM3JQWW9NYWtsclB2YjZ3V3FPWGtpZHhWZGMxMXlLMHFmMGZXQl8tMk1SV0cxRnFlTl9zblpaaXFxSll2LW1OS25Za2diWWd3QWctUWJLVUFGaG5NbDJ3d3RXVWRRTzNnQTdwLUg5aWhzU28tQXE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytomX (CTMX) Q4 2025 Earnings Transcript", "summary": "CytomX Therapeutics announced positive Phase I dose expansion data for Varseta-M in late-line colorectal cancer patients, showing strong anti-tumor activity with confirmed overall response rates of 32% and 20% at its highest dose levels. The company has made significant progress ", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Motley%20Fool/2264920/cytomx-ctmx-q4-2025-earnings-transcript/", "source_name": "The Globe and Mail", "published_at": "2026-06-02T18:10:57", "published_display": "02 Jun 2026 18:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytomX Therapeutics: Cashed Up With Catalysts Ahead (NASDAQ:CTMX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOTE1PcFcwX2lVb0NLLV8xa1BubTFmdUtfMDg5ZkoxVWdJckc3ZnRUR1p0VnlFazNuTl9YX3I5TUZDNlg1U3FrY0oyd0JzVHo2R1RraG1vQkVoeUZXc3lEa29LcDFVQlRJUy1vcXlDZ0xtWXZXV0ktVHJYOUduLUdsSTNwNUxhdnVPZjF4S2kyWG83U3VSSUE?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wolfe Research Initiates Coverage of CytomX Therapeutics (CTMX) with Outperform", "summary": "Wolfe Research initiated coverage of CytomX Therapeutics (CTMX) with an Outperform rating and a $6 price target, citing the company's de-risked EpCAM antibody-drug conjugate. Separately, H.C. Wainwright lowered its price target to $11 from $17, maintaining a Buy rating due to dil", "url": "https://www.insidermonkey.com/blog/wolfe-research-initiates-coverage-of-cytomx-therapeutics-ctmx-with-outperform-1767483/", "source_name": "Insider Monkey", "published_at": "2026-05-22T14:41:00", "published_display": "22 May 2026 14:41", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytomX Therapeutics to Present at Upcoming June Investor Conferences", "summary": "CytomX Therapeutics announced that its management will participate in two investor conferences in June: the Jefferies Global Healthcare Conference on June 4, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026. The company, which focuses on devel", "url": "https://www.manilatimes.net/2026/05/21/tmt-newswire/globenewswire/cytomx-therapeutics-to-present-at-upcoming-june-investor-conferences/2349120", "source_name": "The Manila Times", "published_at": "2026-05-21T11:40:20", "published_display": "21 May 2026 11:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytomx Therapeutics in June investor events at Jefferies, Goldman Sachs", "summary": "CytomX Therapeutics (Nasdaq: CTMX) announced its management will participate in two investor conferences in June 2026: the Jefferies Global Healthcare Conference on June 4th and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10th. The company's management will", "url": "https://www.stocktitan.net/news/CTMX/cytom-x-therapeutics-to-present-at-upcoming-june-investor-am042zwhf03b.html", "source_name": "Stock Titan", "published_at": "2026-05-21T11:40:20", "published_display": "21 May 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wolfe Research Initiates CytomX Therapeutics With Outperform Rating", "summary": "Wolfe Research has initiated coverage of CytomX Therapeutics with an Outperform rating. This indicates a positive outlook from the research firm regarding the pharmaceutical company's stock performance.", "url": "https://www.moomoo.com/news/post/70247022/wolfe-research-initiates-cytomx-therapeutics-with-outperform-rating?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-05-19T16:38:51", "published_display": "19 May 2026 16:38", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wolfe Research initiates CytomX stock with outperform rating", "summary": "Wolfe Research has initiated coverage on CytomX Therapeutics (NASDAQ:CTMX) with an outperform rating and a $3.50 price target, citing promising results from its Varseta-M drug candidate in metastatic colorectal cancer. The company has several catalysts expected within the next 12", "url": "https://www.investing.com/news/analyst-ratings/wolfe-research-initiates-cytomx-stock-with-outperform-rating-93CH-4697986", "source_name": "Investing.com", "published_at": "2026-05-19T11:09:51", "published_display": "19 May 2026 11:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytomX appoints Mamata Gokhale as regulatory affairs head", "summary": "CytomX Therapeutics has appointed Mamata Gokhale, Ph.D., RAC, as its Senior Vice President of Regulatory Affairs. Dr. Gokhale will lead the company's global regulatory strategy, bringing over 25 years of experience in the field. The company, focused on cancer treatments, reported", "url": "https://www.investing.com/news/company-news/cytomx-appoints-mamata-gokhale-as-regulatory-affairs-head-93CH-4695601", "source_name": "Investing.com", "published_at": "2026-05-18T12:39:29", "published_display": "18 May 2026 12:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology: Trading Near Cash Value With A Huge Revenue Opportunity (NASDAQ:VIR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxORjJIeVJSSUdKSGx0Ni15Q0FxNmlJYi03UTdmX3hjaTNoYTZxajNoQXdwa05DRjBPdVBiZEVRWVhOOVI2bTVrdVV0bUNQeGRISVEwaEt6OEVYN3pqSHJsU25JSTFsQkMwS2RoeHNhWUw3bEFuWnZzLTk0X3J6d1ZsM1R4RHBNREMxNUJ6QmRldV9Md3BhOEZRbk0wLUxYZVItRGRTY3YwNWRZblkwM2xSLWpIVV8?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "CytomX\u2019s CX-801 Enters Key Early Cancer Trial Phase, Putting CTMX Back on Investor Radar", "summary": "CytomX Therapeutics (CTMX) announced that its experimental cancer drug, CX-801, has entered a key early-phase clinical trial (CTMX-801-101) for advanced solid tumors. The study, conducted alone and in combination with Merck's Keytruda, aims to assess safety, dosage, and initial a", "url": "https://www.tipranks.com/news/company-announcements/cytomxs-cx-801-enters-key-early-cancer-trial-phase-putting-ctmx-back-on-investor-radar", "source_name": "TipRanks", "published_at": "2026-05-16T02:39:31", "published_display": "16 May 2026 02:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald Initiates Coverage of CytomX Therapeutics (CTMX) with Overweight Recommendation", "summary": "Cantor Fitzgerald has initiated coverage on CytomX Therapeutics (CTMX) with an Overweight rating. This indicates a positive outlook on the company's stock by the analyst firm. The coverage initiation could attract investor interest in CytomX Therapeutics.", "url": "http://www.msn.com/en-us/health/other/cantor-fitzgerald-initiates-coverage-of-cytomx-therapeutics-ctmx-with-overweight-recommendation/ar-AA1N7cL5?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-05-15T20:39:31", "published_display": "15 May 2026 20:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Venrock group files Amendment reporting 9.98M CTMX shares (NASDAQ: CTMX)", "summary": "A Venrock-related group has filed an Amendment to Schedule 13G/A, disclosing beneficial ownership of 9,982,124 shares of CytomX Therapeutics (NASDAQ: CTMX) common stock as of March 31, 2026, representing a 4.6% stake. This stake is split among Venrock Healthcare Capital Partners ", "url": "https://www.stocktitan.net/sec-filings/CTMX/schedule-13g-a-cytom-x-therapeutics-inc-amended-passive-investment-di-6b2ab405780c.html", "source_name": "Stock Titan", "published_at": "2026-05-15T20:39:31", "published_display": "15 May 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Perceptive (CTMX) reports 10,098,824 shares, a 4.6% stake", "summary": "Perceptive Advisors, Joseph Edelman, and Perceptive Life Sciences Master Fund collectively reported beneficial ownership of 10,098,824 shares of CytomX Therapeutics (CTMX) common stock, representing a 4.6% stake. This information was disclosed in an amended Schedule 13G/A SEC fil", "url": "https://www.stocktitan.net/sec-filings/CTMX/schedule-13g-a-cytom-x-therapeutics-inc-amended-passive-investment-di-0f3a6935d586.html", "source_name": "Stock Titan", "published_at": "2026-05-15T19:39:31", "published_display": "15 May 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seven Fleet group beneficially owns 1,085,398 CTMX shares (NASDAQ: CTMX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQbi16YmkyYnB5bGJJS2hoSDJpZE5YVnQtdHp1dWFCc19oMUM4Rm40ZnpZb2ctYzNqZlVObWZkX1BoejlURUFpQVc1N054WkNiWXIyVVlBdzZ2VmJSb2VxUXNKYXpET2RielA2SnpuUnR3cmFHdlhlVXZ0Ri1vVlRBejk3eFBvaEVTSjhqNC1BLWhYRlRYTUEyUDJMQlFfRHRTb1VDdFdLNzZwTjNTeFFMR2RmVms4S0RsQmFnVy1YY3Z5S1pfRzl6OVVGYw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "CytomX Therapeutics stock (US23284F1057): Recent price volatility draws attention", "summary": "CytomX Therapeutics (CTMX) stock experienced a 2.32% decline to $3.79 on May 13, 2026, driven by ongoing clinical developments in oncology and exhibiting moderate volatility. The biopharma company focuses on developing conditionally activated biologics, including PROBODY therapeu", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/cytomx-therapeutics-stock-us23284f1057-recent-price-volatility-draws/69334356", "source_name": "AD HOC NEWS", "published_at": "2026-05-14T13:08:57", "published_display": "14 May 2026 13:08", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Broker Revenue Forecasts For CytomX Therapeutics, Inc. (NASDAQ:CTMX) Are Surging Higher", "summary": "Analysts have significantly upgraded revenue forecasts for CytomX Therapeutics, Inc. for 2026, with estimates rising from US$22 million to US$35 million, and reducing projected per-share losses. Despite the improved outlook, analysts have maintained their price target of US$13.00", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ctmx/cytomx-therapeutics/news/broker-revenue-forecasts-for-cytomx-therapeutics-inc-nasdaqc", "source_name": "Simply Wall Street", "published_at": "2026-05-13T11:39:10", "published_display": "13 May 2026 11:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytomX Therapeutics (NasdaqGS:CTMX) Stock Forecast & Analyst Predictions", "summary": "CytomX Therapeutics (CTMX) is forecast to grow earnings by 2.4% and revenue by 36.5% annually. Recent analyst revisions for 2026 revenue have increased by 52%, with expected loss reductions. Despite positive clinical data for its lead programs, the company faces risks such as sha", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ctmx/cytomx-therapeutics/future", "source_name": "Simply Wall Street", "published_at": "2026-05-12T15:10:03", "published_display": "12 May 2026 15:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: CytomX Therapeutics Q1 2026 beats EPS forecast", "summary": "CytomX Therapeutics reported strong Q1 2026 results, surpassing EPS and revenue forecasts, yet its stock declined in after-hours trading. The company's lead candidate, Varseta-M, an EpCAM-targeting ADC, shows promising clinical results in late-line metastatic colorectal cancer, w", "url": "https://www.investing.com/news/transcripts/earnings-call-transcript-cytomx-therapeutics-q1-2026-beats-eps-forecast-93CH-4677690", "source_name": "Investing.com", "published_at": "2026-05-12T14:08:57", "published_display": "12 May 2026 14:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Just Reported And Analysts Are Boosting Their Estimates", "summary": "CytomX Therapeutics (NASDAQ:CTMX) exceeded first-quarter revenue expectations, reporting US$10m, significantly beating forecasts. Despite an anticipated decline in revenue for 2026, analysts have upgraded revenue estimates for the year while maintaining loss per share forecasts. ", "url": "https://www.sahmcapital.com/news/content/earnings-update-cytomx-therapeutics-inc-nasdaqctmx-just-reported-and-analysts-are-boosting-their-estimates-2026-05-11", "source_name": "Sahm", "published_at": "2026-05-12T01:39:57", "published_display": "12 May 2026 01:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Beat: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQdUNlVXN6dFU3c1BrRkRsREktcE4xZXVHR1Y4ZUFzanY3clNHTzZrelJlek1WRTBoWkNrRTBBRVNXX1BoZTdZNVdPaW5YQkRBSktZMEREUzdkdWRwNF9lc1VBUkNwd1NMYVFFUkJLTDRTdk5aVmNDdVkybEluckJYUGd6LUJ1ektZUlBiaG4wX3pXVkNEOGRpOVktY1FPRkhJODNnRw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQVng5OWR5WHBENGFILW96MnFob054Tm9BNk5IQkxiRkNBcWk0a1M1QVhaLUVlNEVzcHhxeGp4OE5NWXRXc1pfang5RkdVWHpicjVvZDB5SS1CaDdxcWpCU1NvaktaaEhZcHlPWjViZnNRbmFqcWZTVXpfVGk5Q1hsZWRkVXFUVElybzFldmZweTJ4YWJLbzIyQ0RiSUM1b1FNN0ZJNU9pLVdqQnZLdkdMZUo5WHBwSldVRjU1VjVfZlQ1UQ?oc=5", "source_name": "TradingView", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "CytomX Therapeutics, Inc. (CTMX) A Top Healthcare Penny Stock Amid Colorectal Cancer Treatment Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNa3JEamtmRWRxcnZPYmtub0RTUmYzZ1AxNUV4QXhucXZINGVkbXF5WEc1d1BkcEtTM3JNR05nOTFRMXhiU2tMSzVLbXlOdUt4djdZUFlvcEptdTFmVmVVdW8tVHdzNGtGcjVHS0ZfUjdaQ3l1QnNpUUFpZjVZMF90aWZNNGNBUjdJMm83bkc5UlI4bERKTXJUQjZLbkhCZk1oai1R?oc=5", "source_name": "Market source", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The CytomX Therapeutics (CTMX) Narrative Is Shifting With New Colorectal Cancer Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPNjVmbVpwOVZTTUd1cmItMVpZWWZ1eWpqeTVvMmI0SzRoMlV0LUpxOTg0UVd6R0dNZWZJOHVNU2g4NjN6dzZib0lsSUxwclNOYnhXRkdSNTRFMWhRYmtCUzlXa2lweVk2ZGFySzhiSHY2YndtbjlfenduNXhfS0R1UHJLR2dmOFphczR4ZFMtOEZWdTd4YjBsZEktV0ZSY2c1aWlpUE9QRjlkR0RVc05lZG53?oc=5", "source_name": "Market source", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Investors Are Reacting To CytomX Therapeutics (CTMX) Equity Raise And Encouraging Varseta-M Trial Data", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-20T07:00:00+00:00", "published_display": "20 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytomX Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQZHdfUVpjemtkQ1NjUDZzSlktV2taZllxNDROWl9XN3VNaXVtTVFVblhvUXpnQmQycURFcDlDakhQZmd2LTNncllsanVMU1FRVDJkS0tYelJQZ2phR09yOG9NcTQzbUN0SVZjQjd2TzRyOFZfb0ZnYnB3cTNuOG5NcnNUMTBUaVBSRjQydWJmY3JnOXFxOW1VR00zSk16a0UwNDMzaWpsRktZQzExWHcwWkFsRGVkRG9FNXRSMA?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At CytomX Therapeutics (CTMX) Valuation After Varseta M Phase 1 Expansion Data And Earnings Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxPWmFKYTVmN25KeE9uaW0yNWR0V3d4NjJMejZLUGxmRURGaXU5YTVZeUNGcVY1UGhaRUUwVUV4dTJIWmNmd1hCS2psTHBodHBwRi1xdG5Qc3dhRzluUmpLQlNpQ0pucnVNdjB0UTNpVElhNXg1TlByYXNzY2lWTmZrQXh3UjNYdC1LWkF3WUliRG50SlQtNEh4cWJ3WTBHSmRfSEFyclB6UWJ2MjBOMzBiTUlBRzVoWkIteDZHb1V1aTRsV1YyNkNHN0plcXpkUU43UTdvczBEMlhKRDR5LUJkcUVrWXhKeGxo0gHuAUFVX3lxTE8xZFc4dFNWeGc5VW5acVZISllCY3dNNkpCdXVRcWJGMVdhTUR2eUF3OEprRTY4X2JzY2R6aUUwcGFiUm81bmxJVGZDVTJBaTVUdnBFZDUzMlFVUTZKaTJQRGF4aE1HemlHLWotRDhnbFBiRmVRNG1xdnhULWtzcnlxQ3IySEFMRjNNWUpjYlhiY1pFd0FZVkVRZXMwVUd5aXZFYnN2a2JjVTlGZHJuZDR1ZzdscmYzUHpFWW5fcXBWMnV0aG00b2pnd2w1MUt6ejdoT2dOeDhFam9sbWZrOUxpa0ltdER3cndJNWMzUHc?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech CytomX prices $250M stock sale to fund Varseta-M", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOc3kyVVlidFE0elI2eFBjbEN0a0g4ZHZoUnk4WTdldWM0VGJtM0VGLVZ6d3lDQW4ySVlpbHNhNnBDUFZhb0xSQWlyZ09oa0lJQ2Y2VUpEQk1RUzZORnZISGFVXzRpejF5WHhmR2Y5eGVDSTNkM3FXYjFKLWVUZ09YQzMzMm4wbTg1X245eUdsMDQ5cHU3eF9ZdzZFT2JpYlg4WDJ2enlMNkRLcmRjOXRsbTlKbklEUHJGVUk5Tw?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_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?oc=5", "source_name": "The Manila Times", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQcExPemExZ1RKWUFGVHVnVVpGQkVJd1pQdkhzeFREVGpGNklQdGVVVHlVYnV3YndNc0xxblNXX3NNSURxTXBPMnJvTDZxOFBaODNwSnhEV3MtWlJ6MFRYbDhQNWhXSFJGZ3p0a1lEU2FzOHg5MUloTUFENXpZSkNVMmtoVmxIenUyQ29YWmZWU1g?oc=5", "source_name": "Market source", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytomX seeks $250M stock sale to fund Varseta-M, pipeline programs", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPdTZtSi12VFZuVnprLVU2bWxRZjI5U0ZKV3ZBRko4c25Sc3JXRFpzSkpxN3ltMU5PcF9PWmtDeFhYQkU3eXVlQUNmbHh0dk41ZG1vVHMwRzB3U0hxQTlMWDR0V3hscE9Sa0tsdC1pbjJEd1lqNXNNemZQWFVOeVZUVVJ6eEY3UWtuS0haYVJSWm5PbjV1LW91YmJHVzBOc01NOHpNN2dJZzJNQUNFdmV3RkRlYjk2QnNjZ2FDZQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Colorectal cancer patients with few options see 32% response from CytomX drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOTHFaMnVPaVowNlhvUmQ0S19zdmo3MWRQOXp4ZWc1cGliNnAzNUlITU51RkdSdkFSZm51OXlkVmJxR25YeEJFRVV0OG5ROHpwY201WlY2TTZSMDhUVUlnM0ROS1VUZ2s1eGRIUC0wMUticnlfcGk4Y3dDNDEzUWsxV21rcHRZb0hYRVdNWGdZMGdJQ0J1VFprWmFzaWRfQjBBajlQU2hyRnV6Vm4zMmVpeDJVWXBWWmNT?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytomX jumps as investors react to fresh Varseta-M colorectal cancer update alongside FY2025 results", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxQRW1PUkUyMFloZGVLZVVLZVo2Q3N1MXpGZVJtd3JfTkJqcFl0cTVacjhDQW5wUjhneE1zaDl3NktKSUwzQXI0dktzZFF5V2VQX0dLVWc0S3dwOFpTZUxZWl8zc2ZsX0tTdWdIdFFiUWNBX2twRk42Qmw0QjVsRzcyMlhnMjFUQlRGZ1lJSzN3OG5hTXIwNnhWcXNDSFU0Z3BaVHFsZHVMWk9fNDRmclB6M01FQlVPQmJuY1NYZUpZX3ptR213c3Z3eTNJVmdHQQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-23T08:00:00+00:00", "published_display": "23 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytomX Therapeutics' (NASDAQ:CTMX) investors will be pleased with their incredible 402% return over the last year", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxOT1FRem85RWxHOGpFOGpYTFF2ZXY3Zm96TktieHFMZWRUSi1EYzJsRjZmOXRkWC1fVWZsNTlnUGs1QXgxdTdGamlkNWE1THdFYUM3ZDN6dXg4SUtfTVdUeUpZTHBtSVRQQ2VtRWVfZ0F4VEIxeE5LdUZkOUVveDBUVzJTSWk1MEtnY2ZrZGFyS00?oc=5", "source_name": "Market source", "published_at": "2026-01-16T08:00:00+00:00", "published_display": "16 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "by_tier": {"direct": [{"title": "Is CytomX (CTMX) One of the Best Growth Stocks Under $30 to Buy Now?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "Insider Monkey", "published_at": "2026-06-19T07:03:49+00:00", "published_display": "19 Jun 2026 07:03", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytomX Therapeutics (CTMX) CFO sells shares to cover RSU tax withholding", "summary": "CytomX Therapeutics CFO Christopher Ogden sold 1,624 shares of common stock on June 15, 2026, at an average price of $3.05 per share. This sale was a non-discretionary tax-related event to cover withholding obligations from the vesting of restricted stock units. Following the tra", "url": "https://www.stocktitan.net/sec-filings/CTMX/form-4-cytom-x-therapeutics-inc-insider-trading-activity-bf83af5e2c48.html", "source_name": "Stock Titan", "published_at": "2026-06-18T00:40:33", "published_display": "18 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytomX CFO Ogden sells $4,953 in company stock By Investing.com", "summary": "CytomX Therapeutics CFO Christopher Ogden sold 1,624 shares of company stock for $4,953 to cover tax obligations related to restricted stock units. Following the sale, Ogden directly holds 295,324 shares. This transaction occurs as CTMX shares are down 31% year-to-date and are co", "url": "https://in.investing.com/news/insider-trading-news/cytomx-cfo-ogden-sells-4953-in-company-stock-93CH-5460658", "source_name": "Investing.com India", "published_at": "2026-06-18T00:09:14", "published_display": "18 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytomX Therapeutics Inc (CTMX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides a revenue breakdown for CytomX Therapeutics Inc (CTMX). It notes that relevant data for business segments and current fiscal year quarters (FY2025, FY2025Q4, FY2025Q3, FY2025Q1) have not yet been disclosed by the company. However, it does sho", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ctmx/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T19:40:33", "published_display": "17 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10 Best Growth Stocks Under $30 to Buy Now", "summary": "The article highlights CytomX Therapeutics Inc. (NASDAQ: CTMX) as one of the best growth stocks under $30. It details CytomX's expanded research collaboration with Regeneron to develop next-generation bispecific cancer therapies, a deal potentially worth up to $4 billion. CytomX ", "url": "https://www.insidermonkey.com/blog/10-best-growth-stocks-under-30-to-buy-now-1782530/2", "source_name": "Insider Monkey", "published_at": "2026-06-17T17:09:14", "published_display": "17 Jun 2026 17:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytomX Therapeutics Inc (CTMX) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of CytomX Therapeutics Inc (CTMX), noting its current valuation score of 7.83 within the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -5.63 and mentions that P/B, P/S, and P/CF data have not been di", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ctmx/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T09:39:29", "published_display": "17 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytomX Therapeutics Inc (CTMX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "CytomX Therapeutics Inc (CTMX) has an earnings forecast score of 9.00, placing it 14th in the Biotechnology & Medical Research industry. Analysts have a \"Strong Buy\" rating with an average price target of $6.50. The company's expected revenue for the next quarter is $12.31M, with", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ctmx/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T08:39:29", "published_display": "17 Jun 2026 08:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Narrative Around CytomX Therapeutics (CTMX) Is Evolving With Recent Developments", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPSFU0a3JINkJxb2lNd21YZlpWdUc1aWU1Wkl0dXdZbElXeHhndkhhQ0d6eGt2am1DMXRVV2FBOVBmbDFOYkkwSzVtQm5GcXRXZHZSRGl4RE96ZVpFUWFwMlRYZGZLbVVOMXVJYVFIMmtSdWt6QTZTTzJkMktaZTEzZ3JtVi1aTU1TNzZ1cHRvemx4OU5RN2pOTUd0emUzX0s0bjRmZmotM2RyQQ?oc=5", "source_name": "Market source", "published_at": "2026-06-11T17:12:46+00:00", "published_display": "11 Jun 2026 17:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CTMX Stock Garners Price Target Revisions After Colorectal Cancer Trial Data: Jefferies Sees As Much As 230% Upside", "summary": "Following positive early-stage trial data for its lead asset Varseta-M in metastatic colorectal cancer, CytomX Therapeutics (CTMX) has received multiple price target revisions from analysts. Jefferies raised its price target to $16-$18, indicating a potential upside of up to 230%", "url": "https://stocktwits.com/news-articles/markets/equity/ctmx-stock-garners-price-target-revisions-after-colorectal-cancer-trial-data/cZ37k5oRIWc", "source_name": "Stocktwits", "published_at": "2026-06-09T22:39:32", "published_display": "09 Jun 2026 22:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Schulhoff & Co. Inc. Acquires Shares of 374,850 CytomX Therapeutics, Inc. $CTMX", "summary": "Schulhoff & Co. Inc. has acquired a new stake of 374,850 shares in CytomX Therapeutics, Inc. (NASDAQ:CTMX) during the fourth quarter, valued at approximately $1.6 million. This investment highlights broader institutional interest, with hedge funds and other institutional investor", "url": "https://www.marketbeat.com/instant-alerts/filing-schulhoff-co-inc-acquires-shares-of-374850-cytomx-therapeutics-inc-ctmx-2026-06-08/", "source_name": "MarketBeat", "published_at": "2026-06-08T14:09:17", "published_display": "08 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CTMX: Varseta-M shows strong efficacy in late-line CRC, with pivotal trials and new partnerships advancing", "summary": "CytomX Therapeutics (CTMX) has made significant progress with its Probody platform and expanded its collaboration with Regeneron, securing substantial funding. Their drug Varseta-M has shown strong efficacy and a manageable safety profile in advanced colorectal cancer, with pivot", "url": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3480519:0-ctmx-varseta-m-shows-strong-efficacy-in-late-line-crc-with-pivotal-trials-and-new-partnerships-advancing/", "source_name": "TradingView", "published_at": "2026-06-04T20:10:42", "published_display": "04 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytomX Therapeutics (Nasdaq:CTMX) - Stock Analysis", "summary": "CytomX Therapeutics (CTMX) is an oncology-focused biopharmaceutical company with a market cap of US$692.3m. The stock is considered 70.0% undervalued by analysts and its revenue is forecast to grow 37.37% per year, despite being currently unprofitable. Recent updates include posi", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ctmx/cytomx-therapeutics", "source_name": "Simply Wall Street", "published_at": "2026-06-04T12:08:44", "published_display": "04 Jun 2026 12:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytomX gains as licensing deal with Regeneron expands", "summary": "CytomX Therapeutics saw its shares rise following an expanded licensing agreement with Regeneron Pharmaceuticals. The deal builds on a collaboration initiated in 2021, focusing on the development of bispecific anticancer therapeutics using CytomX's Probody platform. Under the new", "url": "https://www.msn.com/en-us/health/other/cytomx-gains-as-licensing-deal-with-regeneron-expands/ar-AA24KeJw?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-06-03T16:41:29", "published_display": "03 Jun 2026 16:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inside CytomX\u2019s new cancer alliance with Regeneron, worth up to $4B", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNM1JqTGl0dWdIanhJU05QVl9DZ05sb3lSWS1uaDlwU0hJV29Pa1dncEE3VUJSeFg3YUxyQjVKNE9sdVhJdWhYVDI4UFNxTlhfdVoxM3JQWW9NYWtsclB2YjZ3V3FPWGtpZHhWZGMxMXlLMHFmMGZXQl8tMk1SV0cxRnFlTl9zblpaaXFxSll2LW1OS25Za2diWWd3QWctUWJLVUFGaG5NbDJ3d3RXVWRRTzNnQTdwLUg5aWhzU28tQXE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytomX (CTMX) Q4 2025 Earnings Transcript", "summary": "CytomX Therapeutics announced positive Phase I dose expansion data for Varseta-M in late-line colorectal cancer patients, showing strong anti-tumor activity with confirmed overall response rates of 32% and 20% at its highest dose levels. The company has made significant progress ", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Motley%20Fool/2264920/cytomx-ctmx-q4-2025-earnings-transcript/", "source_name": "The Globe and Mail", "published_at": "2026-06-02T18:10:57", "published_display": "02 Jun 2026 18:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytomX Therapeutics: Cashed Up With Catalysts Ahead (NASDAQ:CTMX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOTE1PcFcwX2lVb0NLLV8xa1BubTFmdUtfMDg5ZkoxVWdJckc3ZnRUR1p0VnlFazNuTl9YX3I5TUZDNlg1U3FrY0oyd0JzVHo2R1RraG1vQkVoeUZXc3lEa29LcDFVQlRJUy1vcXlDZ0xtWXZXV0ktVHJYOUduLUdsSTNwNUxhdnVPZjF4S2kyWG83U3VSSUE?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wolfe Research Initiates Coverage of CytomX Therapeutics (CTMX) with Outperform", "summary": "Wolfe Research initiated coverage of CytomX Therapeutics (CTMX) with an Outperform rating and a $6 price target, citing the company's de-risked EpCAM antibody-drug conjugate. Separately, H.C. Wainwright lowered its price target to $11 from $17, maintaining a Buy rating due to dil", "url": "https://www.insidermonkey.com/blog/wolfe-research-initiates-coverage-of-cytomx-therapeutics-ctmx-with-outperform-1767483/", "source_name": "Insider Monkey", "published_at": "2026-05-22T14:41:00", "published_display": "22 May 2026 14:41", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytomX Therapeutics to Present at Upcoming June Investor Conferences", "summary": "CytomX Therapeutics announced that its management will participate in two investor conferences in June: the Jefferies Global Healthcare Conference on June 4, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026. The company, which focuses on devel", "url": "https://www.manilatimes.net/2026/05/21/tmt-newswire/globenewswire/cytomx-therapeutics-to-present-at-upcoming-june-investor-conferences/2349120", "source_name": "The Manila Times", "published_at": "2026-05-21T11:40:20", "published_display": "21 May 2026 11:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytomx Therapeutics in June investor events at Jefferies, Goldman Sachs", "summary": "CytomX Therapeutics (Nasdaq: CTMX) announced its management will participate in two investor conferences in June 2026: the Jefferies Global Healthcare Conference on June 4th and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10th. The company's management will", "url": "https://www.stocktitan.net/news/CTMX/cytom-x-therapeutics-to-present-at-upcoming-june-investor-am042zwhf03b.html", "source_name": "Stock Titan", "published_at": "2026-05-21T11:40:20", "published_display": "21 May 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wolfe Research Initiates CytomX Therapeutics With Outperform Rating", "summary": "Wolfe Research has initiated coverage of CytomX Therapeutics with an Outperform rating. This indicates a positive outlook from the research firm regarding the pharmaceutical company's stock performance.", "url": "https://www.moomoo.com/news/post/70247022/wolfe-research-initiates-cytomx-therapeutics-with-outperform-rating?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-05-19T16:38:51", "published_display": "19 May 2026 16:38", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wolfe Research initiates CytomX stock with outperform rating", "summary": "Wolfe Research has initiated coverage on CytomX Therapeutics (NASDAQ:CTMX) with an outperform rating and a $3.50 price target, citing promising results from its Varseta-M drug candidate in metastatic colorectal cancer. The company has several catalysts expected within the next 12", "url": "https://www.investing.com/news/analyst-ratings/wolfe-research-initiates-cytomx-stock-with-outperform-rating-93CH-4697986", "source_name": "Investing.com", "published_at": "2026-05-19T11:09:51", "published_display": "19 May 2026 11:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytomX appoints Mamata Gokhale as regulatory affairs head", "summary": "CytomX Therapeutics has appointed Mamata Gokhale, Ph.D., RAC, as its Senior Vice President of Regulatory Affairs. Dr. Gokhale will lead the company's global regulatory strategy, bringing over 25 years of experience in the field. The company, focused on cancer treatments, reported", "url": "https://www.investing.com/news/company-news/cytomx-appoints-mamata-gokhale-as-regulatory-affairs-head-93CH-4695601", "source_name": "Investing.com", "published_at": "2026-05-18T12:39:29", "published_display": "18 May 2026 12:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytomX\u2019s CX-801 Enters Key Early Cancer Trial Phase, Putting CTMX Back on Investor Radar", "summary": "CytomX Therapeutics (CTMX) announced that its experimental cancer drug, CX-801, has entered a key early-phase clinical trial (CTMX-801-101) for advanced solid tumors. The study, conducted alone and in combination with Merck's Keytruda, aims to assess safety, dosage, and initial a", "url": "https://www.tipranks.com/news/company-announcements/cytomxs-cx-801-enters-key-early-cancer-trial-phase-putting-ctmx-back-on-investor-radar", "source_name": "TipRanks", "published_at": "2026-05-16T02:39:31", "published_display": "16 May 2026 02:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald Initiates Coverage of CytomX Therapeutics (CTMX) with Overweight Recommendation", "summary": "Cantor Fitzgerald has initiated coverage on CytomX Therapeutics (CTMX) with an Overweight rating. This indicates a positive outlook on the company's stock by the analyst firm. The coverage initiation could attract investor interest in CytomX Therapeutics.", "url": "http://www.msn.com/en-us/health/other/cantor-fitzgerald-initiates-coverage-of-cytomx-therapeutics-ctmx-with-overweight-recommendation/ar-AA1N7cL5?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-05-15T20:39:31", "published_display": "15 May 2026 20:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Venrock group files Amendment reporting 9.98M CTMX shares (NASDAQ: CTMX)", "summary": "A Venrock-related group has filed an Amendment to Schedule 13G/A, disclosing beneficial ownership of 9,982,124 shares of CytomX Therapeutics (NASDAQ: CTMX) common stock as of March 31, 2026, representing a 4.6% stake. This stake is split among Venrock Healthcare Capital Partners ", "url": "https://www.stocktitan.net/sec-filings/CTMX/schedule-13g-a-cytom-x-therapeutics-inc-amended-passive-investment-di-6b2ab405780c.html", "source_name": "Stock Titan", "published_at": "2026-05-15T20:39:31", "published_display": "15 May 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Perceptive (CTMX) reports 10,098,824 shares, a 4.6% stake", "summary": "Perceptive Advisors, Joseph Edelman, and Perceptive Life Sciences Master Fund collectively reported beneficial ownership of 10,098,824 shares of CytomX Therapeutics (CTMX) common stock, representing a 4.6% stake. This information was disclosed in an amended Schedule 13G/A SEC fil", "url": "https://www.stocktitan.net/sec-filings/CTMX/schedule-13g-a-cytom-x-therapeutics-inc-amended-passive-investment-di-0f3a6935d586.html", "source_name": "Stock Titan", "published_at": "2026-05-15T19:39:31", "published_display": "15 May 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seven Fleet group beneficially owns 1,085,398 CTMX shares (NASDAQ: CTMX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQbi16YmkyYnB5bGJJS2hoSDJpZE5YVnQtdHp1dWFCc19oMUM4Rm40ZnpZb2ctYzNqZlVObWZkX1BoejlURUFpQVc1N054WkNiWXIyVVlBdzZ2VmJSb2VxUXNKYXpET2RielA2SnpuUnR3cmFHdlhlVXZ0Ri1vVlRBejk3eFBvaEVTSjhqNC1BLWhYRlRYTUEyUDJMQlFfRHRTb1VDdFdLNzZwTjNTeFFMR2RmVms4S0RsQmFnVy1YY3Z5S1pfRzl6OVVGYw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytomX Therapeutics stock (US23284F1057): Recent price volatility draws attention", "summary": "CytomX Therapeutics (CTMX) stock experienced a 2.32% decline to $3.79 on May 13, 2026, driven by ongoing clinical developments in oncology and exhibiting moderate volatility. The biopharma company focuses on developing conditionally activated biologics, including PROBODY therapeu", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/cytomx-therapeutics-stock-us23284f1057-recent-price-volatility-draws/69334356", "source_name": "AD HOC NEWS", "published_at": "2026-05-14T13:08:57", "published_display": "14 May 2026 13:08", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Broker Revenue Forecasts For CytomX Therapeutics, Inc. (NASDAQ:CTMX) Are Surging Higher", "summary": "Analysts have significantly upgraded revenue forecasts for CytomX Therapeutics, Inc. for 2026, with estimates rising from US$22 million to US$35 million, and reducing projected per-share losses. Despite the improved outlook, analysts have maintained their price target of US$13.00", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ctmx/cytomx-therapeutics/news/broker-revenue-forecasts-for-cytomx-therapeutics-inc-nasdaqc", "source_name": "Simply Wall Street", "published_at": "2026-05-13T11:39:10", "published_display": "13 May 2026 11:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytomX Therapeutics (NasdaqGS:CTMX) Stock Forecast & Analyst Predictions", "summary": "CytomX Therapeutics (CTMX) is forecast to grow earnings by 2.4% and revenue by 36.5% annually. Recent analyst revisions for 2026 revenue have increased by 52%, with expected loss reductions. Despite positive clinical data for its lead programs, the company faces risks such as sha", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ctmx/cytomx-therapeutics/future", "source_name": "Simply Wall Street", "published_at": "2026-05-12T15:10:03", "published_display": "12 May 2026 15:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: CytomX Therapeutics Q1 2026 beats EPS forecast", "summary": "CytomX Therapeutics reported strong Q1 2026 results, surpassing EPS and revenue forecasts, yet its stock declined in after-hours trading. The company's lead candidate, Varseta-M, an EpCAM-targeting ADC, shows promising clinical results in late-line metastatic colorectal cancer, w", "url": "https://www.investing.com/news/transcripts/earnings-call-transcript-cytomx-therapeutics-q1-2026-beats-eps-forecast-93CH-4677690", "source_name": "Investing.com", "published_at": "2026-05-12T14:08:57", "published_display": "12 May 2026 14:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Just Reported And Analysts Are Boosting Their Estimates", "summary": "CytomX Therapeutics (NASDAQ:CTMX) exceeded first-quarter revenue expectations, reporting US$10m, significantly beating forecasts. Despite an anticipated decline in revenue for 2026, analysts have upgraded revenue estimates for the year while maintaining loss per share forecasts. ", "url": "https://www.sahmcapital.com/news/content/earnings-update-cytomx-therapeutics-inc-nasdaqctmx-just-reported-and-analysts-are-boosting-their-estimates-2026-05-11", "source_name": "Sahm", "published_at": "2026-05-12T01:39:57", "published_display": "12 May 2026 01:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Beat: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQdUNlVXN6dFU3c1BrRkRsREktcE4xZXVHR1Y4ZUFzanY3clNHTzZrelJlek1WRTBoWkNrRTBBRVNXX1BoZTdZNVdPaW5YQkRBSktZMEREUzdkdWRwNF9lc1VBUkNwd1NMYVFFUkJLTDRTdk5aVmNDdVkybEluckJYUGd6LUJ1ektZUlBiaG4wX3pXVkNEOGRpOVktY1FPRkhJODNnRw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytomX Therapeutics, Inc. (CTMX) A Top Healthcare Penny Stock Amid Colorectal Cancer Treatment Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNa3JEamtmRWRxcnZPYmtub0RTUmYzZ1AxNUV4QXhucXZINGVkbXF5WEc1d1BkcEtTM3JNR05nOTFRMXhiU2tMSzVLbXlOdUt4djdZUFlvcEptdTFmVmVVdW8tVHdzNGtGcjVHS0ZfUjdaQ3l1QnNpUUFpZjVZMF90aWZNNGNBUjdJMm83bkc5UlI4bERKTXJUQjZLbkhCZk1oai1R?oc=5", "source_name": "Market source", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The CytomX Therapeutics (CTMX) Narrative Is Shifting With New Colorectal Cancer Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPNjVmbVpwOVZTTUd1cmItMVpZWWZ1eWpqeTVvMmI0SzRoMlV0LUpxOTg0UVd6R0dNZWZJOHVNU2g4NjN6dzZib0lsSUxwclNOYnhXRkdSNTRFMWhRYmtCUzlXa2lweVk2ZGFySzhiSHY2YndtbjlfenduNXhfS0R1UHJLR2dmOFphczR4ZFMtOEZWdTd4YjBsZEktV0ZSY2c1aWlpUE9QRjlkR0RVc05lZG53?oc=5", "source_name": "Market source", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Investors Are Reacting To CytomX Therapeutics (CTMX) Equity Raise And Encouraging Varseta-M Trial Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxQTW42R0lWeDFBeW1jZ25RQlhIak9mcXJEWmY2TkFKd1hDa3JBZlZYOTB1b0Y5aUQtYzRfUFhQemtPWVRpcURzWjBkNGtUajlLZE1DRzBsdFotQmVpc0pMaXdmUGhYYlRiRFFsRWwxaHhaa0ZtUG5ZYURGVU14bWZ0dVc3ZHEwWjBkdnl3X1ZSNFR6VFpMZkxLdVlfRFg1ZEhrcVZPT0d0cm8xdFBBTDh6QkJxSExxRjJ6b3Z0OWtFRXFPNUtYdkQwU2NhLTFRQlNfbjh3VzZaTndsNk04Ry16Nzhud0JrTFJH0gHuAUFVX3lxTE16bjVrY3NTbjhSYnVxNHZ1OVoyT0pxR0Fja1FDMFhqaEo2TGxjdGxtTEZfWEljNWh2X1d5SWQzRTBXdDV0LU5NR2M5Nm5mUk1HN0xlcVRTTjVobG9uTlZWbEN1ekFqMllCM2w1S1J2eVlmWUZXREo4d19hY0RXTGtMM25CQUxGUllMWFR4bHlHeVREU3BtOW0yNnNjVUZHNG1INjhrU2NieE1WRlRSX2pjYUlvRjZjeFROX2x5RVp3SVpYOVpZVjBLTmpkbUVzZnlxWnBqRDF1UnhKdzFPejNVeWJLbXB1eFQ5R1hDVUE?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-20T07:00:00+00:00", "published_display": "20 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytomX Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQZHdfUVpjemtkQ1NjUDZzSlktV2taZllxNDROWl9XN3VNaXVtTVFVblhvUXpnQmQycURFcDlDakhQZmd2LTNncllsanVMU1FRVDJkS0tYelJQZ2phR09yOG9NcTQzbUN0SVZjQjd2TzRyOFZfb0ZnYnB3cTNuOG5NcnNUMTBUaVBSRjQydWJmY3JnOXFxOW1VR00zSk16a0UwNDMzaWpsRktZQzExWHcwWkFsRGVkRG9FNXRSMA?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At CytomX Therapeutics (CTMX) Valuation After Varseta M Phase 1 Expansion Data And Earnings Update", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech CytomX prices $250M stock sale to fund Varseta-M", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOc3kyVVlidFE0elI2eFBjbEN0a0g4ZHZoUnk4WTdldWM0VGJtM0VGLVZ6d3lDQW4ySVlpbHNhNnBDUFZhb0xSQWlyZ09oa0lJQ2Y2VUpEQk1RUzZORnZISGFVXzRpejF5WHhmR2Y5eGVDSTNkM3FXYjFKLWVUZ09YQzMzMm4wbTg1X245eUdsMDQ5cHU3eF9ZdzZFT2JpYlg4WDJ2enlMNkRLcmRjOXRsbTlKbklEUHJGVUk5Tw?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_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?oc=5", "source_name": "The Manila Times", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQcExPemExZ1RKWUFGVHVnVVpGQkVJd1pQdkhzeFREVGpGNklQdGVVVHlVYnV3YndNc0xxblNXX3NNSURxTXBPMnJvTDZxOFBaODNwSnhEV3MtWlJ6MFRYbDhQNWhXSFJGZ3p0a1lEU2FzOHg5MUloTUFENXpZSkNVMmtoVmxIenUyQ29YWmZWU1g?oc=5", "source_name": "Market source", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytomX seeks $250M stock sale to fund Varseta-M, pipeline programs", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPdTZtSi12VFZuVnprLVU2bWxRZjI5U0ZKV3ZBRko4c25Sc3JXRFpzSkpxN3ltMU5PcF9PWmtDeFhYQkU3eXVlQUNmbHh0dk41ZG1vVHMwRzB3U0hxQTlMWDR0V3hscE9Sa0tsdC1pbjJEd1lqNXNNemZQWFVOeVZUVVJ6eEY3UWtuS0haYVJSWm5PbjV1LW91YmJHVzBOc01NOHpNN2dJZzJNQUNFdmV3RkRlYjk2QnNjZ2FDZQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Colorectal cancer patients with few options see 32% response from CytomX drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOTHFaMnVPaVowNlhvUmQ0S19zdmo3MWRQOXp4ZWc1cGliNnAzNUlITU51RkdSdkFSZm51OXlkVmJxR25YeEJFRVV0OG5ROHpwY201WlY2TTZSMDhUVUlnM0ROS1VUZ2s1eGRIUC0wMUticnlfcGk4Y3dDNDEzUWsxV21rcHRZb0hYRVdNWGdZMGdJQ0J1VFprWmFzaWRfQjBBajlQU2hyRnV6Vm4zMmVpeDJVWXBWWmNT?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytomX jumps as investors react to fresh Varseta-M colorectal cancer update alongside FY2025 results", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxQRW1PUkUyMFloZGVLZVVLZVo2Q3N1MXpGZVJtd3JfTkJqcFl0cTVacjhDQW5wUjhneE1zaDl3NktKSUwzQXI0dktzZFF5V2VQX0dLVWc0S3dwOFpTZUxZWl8zc2ZsX0tTdWdIdFFiUWNBX2twRk42Qmw0QjVsRzcyMlhnMjFUQlRGZ1lJSzN3OG5hTXIwNnhWcXNDSFU0Z3BaVHFsZHVMWk9fNDRmclB6M01FQlVPQmJuY1NYZUpZX3ptR213c3Z3eTNJVmdHQQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-23T08:00:00+00:00", "published_display": "23 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytomX Therapeutics' (NASDAQ:CTMX) investors will be pleased with their incredible 402% return over the last year", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxOT1FRem85RWxHOGpFOGpYTFF2ZXY3Zm96TktieHFMZWRUSi1EYzJsRjZmOXRkWC1fVWZsNTlnUGs1QXgxdTdGamlkNWE1THdFYUM3ZDN6dXg4SUtfTVdUeUpZTHBtSVRQQ2VtRWVfZ0F4VEIxeE5LdUZkOUVveDBUVzJTSWk1MEtnY2ZrZGFyS00?oc=5", "source_name": "Market source", "published_at": "2026-01-16T08:00:00+00:00", "published_display": "16 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Vir Biotechnology: Trading Near Cash Value With A Huge Revenue Opportunity (NASDAQ:VIR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxORjJIeVJSSUdKSGx0Ni15Q0FxNmlJYi03UTdmX3hjaTNoYTZxajNoQXdwa05DRjBPdVBiZEVRWVhOOVI2bTVrdVV0bUNQeGRISVEwaEt6OEVYN3pqSHJsU25JSTFsQkMwS2RoeHNhWUw3bEFuWnZzLTk0X3J6d1ZsM1R4RHBNREMxNUJ6QmRldV9Md3BhOEZRbk0wLUxYZVItRGRTY3YwNWRZblkwM2xSLWpIVV8?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQVng5OWR5WHBENGFILW96MnFob054Tm9BNk5IQkxiRkNBcWk0a1M1QVhaLUVlNEVzcHhxeGp4OE5NWXRXc1pfang5RkdVWHpicjVvZDB5SS1CaDdxcWpCU1NvaktaaEhZcHlPWjViZnNRbmFqcWZTVXpfVGk5Q1hsZWRkVXFUVElybzFldmZweTJ4YWJLbzIyQ0RiSUM1b1FNN0ZJNU9pLVdqQnZLdkdMZUo5WHBwSldVRjU1VjVfZlQ1UQ?oc=5", "source_name": "TradingView", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 93, "total_relevant": 53, "sentiment_summary": {"positive": 22, "negative": 2, "neutral": 29, "score": 60, "total": 53, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 76, "events": [{"event": "general", "label": "Market update", "weight": 13.55, "count": 24}, {"event": "earnings", "label": "Earnings", "weight": 9.75, "count": 19}, {"event": "analyst", "label": "Analyst action", "weight": 2.75, "count": 5}, {"event": "deals", "label": "Deals and strategy", "weight": 2.2, "count": 4}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 22, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 3.01, "latest_week": "2026-06-12", "one_week_move": 0.3, "four_week_move": -16.6, "twelve_week_move": -32.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.444166, "market_dynamics_buy_signal": false, "relative_strength": -30.691756, "fair_value_gap": 38.7, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "negative", "expectation_probability": 41.5865, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.3% over one week, -16.6% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 59, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 9}, {"label": "Market source", "count": 9}, {"label": "simplywall.st", "count": 5}, {"label": "Insider Monkey", "count": 3}, {"label": "TradingKey", "count": 3}, {"label": "Simply Wall Street", "count": 3}, {"label": "Investing.com", "count": 3}, {"label": "TradingView", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 46}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 24}, {"label": "Earnings", "count": 19}, {"label": "Analyst action", "count": 5}, {"label": "Deals and strategy", "count": 4}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "60/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "46", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+0.3% over one week, -16.6% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Is CytomX (CTMX) One of the Best Growth Stocks Under $30 to Buy Now?"}], "updated_at": "2026-06-19T13:51:34.931294+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}